Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Short term Debt (2022)

Mereo BioPharma (MREO) has disclosed Short term Debt for 1 consecutive years, with $486000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Short term Debt changed N/A to $486000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $486000.0, a N/A change, with the full-year FY2022 number at $486000.0, changed N/A from a year prior.
  • Short term Debt was $486000.0 for Q4 2022 at Mereo BioPharma.
  • In the past five years, Short term Debt ranged from a high of $486000.0 in Q4 2022 to a low of $486000.0 in Q4 2022.